Introduction
Human papillomaviruses (HPVs) comprise at least 100 different virus types, of which roughly 30 are associated with lesions of the anogenital tract (1) . Infection with high-risk types of HPV is a well-established risk factor for the development of cervical carcinoma, which is the second most common form of cancer among women worldwide. Benign and low-grade intraepithelial lesions contain mostly the viral sequences only as episomes (1) (2) (3) . However, viral DNA integrated into host genome is found in nearly all cases of cervical carcinoma, their metastasis and derivative cell lines (4) (5) (6) (7) (8) . Cells carrying integrated viral DNA grow better in vitro, and integration has been correlated with poor prognosis (9, 10) .
The integration of HPV sequences into the host genome might occur randomly or with a preference in or near fragile sites or oncogenes (11) (12) (13) (14) (15) . A consequence of integration is the disruption of the episomal form and more or less extensive deletions in the HPV E1/E2 region. Thus, a repressor function of the E2 protein is eliminated, resulting in an elevated transcription of the E6 and E7 oncogenes. Continuous expression of the E6 and E7 oncoproteins is most probably required for maintenance of the malignant state (16) (17) (18) . These oncogenic proteins interfere with the normal cell cycle, by binding and inactivating the p53 and Rb tumor suppressor proteins, respectively (19) (20) (21) (22) (23) (24) .
In this study, we used the HPV 33-positive cell line UT-DEC-1, derived from a vaginal intraepithelial neoplasia (VAIN I) lesion (25) , as a model system to further clarify the role of HPV integration in cancer progression. The HPV 33 prototype was originally cloned from an invasive cervical carcinoma, and belongs to the group of high-risk HPV types (26) . This HPV type has been found in 4-10% of cervical carcinomas and its precursors, most strikingly, in 50% of tonsillar carcinomas (27, 28) . The genomic organization of HPV 33 is similar to that of other papillomaviruses (29) . The upstream regulatory region of the virus, however, contains a 78 bp perfect tandem repeat, which is not found in the genomes of other HPV types. This tandem repeat harbors an enhancer of the viral early promoter and in the transcription of the early region, there are some features that are specific for HPV 33. Studies of variability in the HPV 33 genome have been restricted previously to the consensus region of L1 (30) .
The UT-DEC-1 cell line progressed to a transformed phenotype during passaging, and acquired independence for additional growth factors, as well as anchorage support, during clonal growth (25) . Furthermore, there was evidence for a change of the episomal form of HPV 33 to a form integrated into the cellular DNA during passaging (25, 31) . Thus, this cell line is potentially useful for studies on such integration events in transformation and progression in HPV-associated carcinogenesis.
In this study, we determined the physical state and genomic variability of HPV 33 at different passages of the UT-DEC-1 cell line to further elucidate HPV-induced pathogenesis. We have mapped the integration site both in the viral and human genome, and quantified episomal and integrated forms of HPV 33 during passaging using a real-time PCR. We report the single copy heterozygote integration site of HPV 33 DNA in chromosome 5p14 in the UT-DEC cell line. This viral-cellular DNA recombination is non-homologous and causes the deletion of viral DNA, only. The identified genomic region is likely to be implicated in the tumor phenotype.
Materials and methods

Cell culture
The UT-DEC-1 cell line was derived from a HPV 33-positive VAIN I lesion as described by Hietanen et al. (25) (Figure 1 ). At the time of establishment, the cells were cultured in D-MEM supplemented with 1% non-essential amino acids, 2 mM L-glutamine, 50 µg/ml streptomycin, 100 U/ml penicillin, 1 µM dexamethasone, 10 ng/ml human recombinant epidermal growth factor and 10% fetal calf serum. From passage 19 onwards, the cells became independent of dexamethasone and epidermal growth factor. Early passage cells for present analyses were taken from cryo-preserved stocks and cultured in serum-free keratinocyte medium (Keratinocyte-SFM, Gibco, Paisley, UK).
PCR for mapping the viral genome DNA was extracted from the UT-DEC-1 cell line according to the method of Miller et al. (32) . PCR was carried out in a 50 µl reaction mixture containing 250 ng of DNA sample, 20 pmol of each primer, 200 µM of each deoxynucleotide triphosphate and 1 U AmpliTaq Gold™ DNA polymerase (Perkin Elmer, Roche Molecular Systems, Branchburg, NJ) in enzyme-specific GeneAmp ® PCR buffer (Perkin Elmer). The template DNA was first denatured at 94°C for 10 min, after which 35 amplification cycles were carried out as follows: DNA denaturation at 94°C for 1 min, annealing at 55-60°C for 1 min and extension at 72°C for 1 min. The final extension step was prolonged with another 7 min at 72°C. The PCR products were analyzed on ethidium bromidestained agarose gel (SeaKem LE agarose, FMC Bioproducts, Rockland, ME).
Assay for integration
Integration (3Ј breakpoint) was scored using the APOT (amplification of papillomavirus oncogene transcripts) assay of Ruediger et al. (33) developed for HPV 16. Total RNA was isolated from the UT-DEC-1 cell line with Trizol 1058 (Life Technologies, Gibco-BRL, Karlsruhe, Germany). cDNA was synthesized from 5 µg of total RNA in a 33 µl reaction volume with First-Strand synthesis kit (Amersham Pharmacia Biotech, Uppsala, Sweden) and was primed using the oligo(dT) 17 adaptor primer, as described by Ruediger et al. (33) . The PCR products were generated using the HPV 33 upstream E6 or E7 primers described by Snijders et al. (34) , together with the downstream adaptor primer. The 5Ј flanking sequence was identified with PCR, using serial primers targeting the 5Ј sequence of the identified chromosomal sequence (accession no. AC032041) and HPV 33-specific primers present in the integrated virus E2 ORF.
Subcloning of UT-DEC-1 cells and detection of integration site
Subcloning of passage 92 cells was carried out by plating the cells in eight 96 well plates at a dilution of maximally 1 cell/well. Clonal growth was observed in 22 wells from which the subclones were successfully isolated. These subclones were first tested for the presence of the E6 ORF and then analyzed for the presence of identified flanking sites with PCR using primer pairs in the human/HPV 33 E2 (5Ј end; human, 5Ј-3Ј AGTGAGC-TAACCGTCATCTG; HPV 33 E2 5Ј-3Ј TGGATGACATAGAACTATA-CAAC) and HPV 33 E1/human (3Ј end, primers as given in Table I ) parts. The PCR program was: denaturation at 94°C for 10 min; 35 cycles of denaturation 94°C for 30 s, annealing at 55°C for 30 s and extension at 72°C for 1 min; final extension at 72°C, for 7 min. The amplicons were analyzed using agarose gel electrophoresis.
Purification and sequencing of the PCR products
The PCR products were separated in SeaKem agarose gels with l HindIII or PhiX174 HaeIII (Promega, Madison, WI, USA) as markers, and purified using QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) or excised from the agarose gel and purified using QIAquick Gel Extraction kit (Qiagen). Sequencing reactions were made using the ABI PRISM BigDye™ Terminator Cycle Sequencing Kit (PE Applied Biosystems, Perkin Elmer, Norwalk, CT) according to the manufacturer's instructions, and analysis was carried out with automated ABI PRISM 377 DNA Sequencer (PE Applied Biosystems). Sequence analysis was performed using the DNASIS program 2.6 (Hitachi Software Engineering, Yokohama, Japan) and FASTA homology searches.
Real-time PCR
Real-time PCR was performed using the ABI Prism 7700 Sequence Detection System and the TaqMan Universal PCR Master Mix (PE Applied Biosystems). The amplification conditions were: 2 min at 50°C, 10 min at 95°C, a twostep cycle at 95°C for 15 s and 60°C for 60 s for a total of 50 cycles. The primers and probe (Table I) were designed with the aid of the Primer Express program, 1.0b6 (PE Applied Biosystems). For the specific amplification of episomal and integrated forms of HPV 33, the amplimer was designed to span the known integration site at genomic position 1715. Integrated virus was scored using the same upstream primer and probe used for episomal detection, but with a downstream primer from the cellular 3Ј junction sequence obtained in this study ( Figure 2 and Table I ). The sizes of the episomal and integrated amplimers were 160 and 166 bp, respectively. The probe was labeled with FAM (6-carboxyfluorescein) at the 5Ј end and TAMRA (6-carboxy-tetramethylrhodamine) at the 3Ј end. Final concentrations of primers and probe, in a total volume of 50 µl, were 0.3 and 0.1 mM, respectively. Fifty nanograms of DNA, from the different passages, were added to the reaction mixture. A standard curve was obtained by amplification of a dilution series, from 5 to 5 million copies per 5 µl of sterilized water, of a clone of HPV 33 in pBR322 (kindly provided by Prof. Gerard Orth, Institut Pasteur, Paris, France). There was a linear relationship between the C t values plotted against the log of the copy number over the entire range of dilutions (not shown). All samples were also analyzed using the β-actin amplification kit from PE Applied Biosystems, and the HPV 33 copy number values were normalized using the results from these amplifications. At least three 'no template control' reactions were included in each run. All experiments were performed twice in duplicate, with similar results.
Cell mixing experiment
In the cell mixing experiment we mixed late passage cells (passage 160), which contained approximately one integrated virus per cell and no episomal virus and early passage cells (passage 10), which contain high level of episomal virus and very low level of the integrated virus form. The mixing ratios were 1:1, 1:10 and 1:100, respectively. The cells were allowed growth over four passages. Simultaneously cultured early and late passage cells were used as control lines. All cells were cultured and passaged in serum-free keratinocyte medium (Keratinocyte-SFM, Gibco). At each passage the genomic DNA was extracted according to the method of Miller et al. (32) . Episomal and integrated virus copy numbers were analyzed with real-time PCR as described above. a For assay of episomal form, the probe was used with primers 1 and 2 (all in HPV genome), and for assay of integrated form the probe and primer 1 was used with primer 3 (in cellular genome). T m was determined using the Primer Express™ program, 1.0b6 (PE Applied Biosystems).
Karyotyping and 24 color M-FISH analysis
Chromosome preparations for chromosome and fluorescent in situ hybridization (FISH) analysis were done on passage 150 cells using routine cytogenetic methods. For karyotyping the slides were stained with G-banding method and the karyotypes were interpreted using the International System for Cytogenetic Nomenclature criteria (35 
Results
Physical mapping
The UT-DEC-1 cell line has now been propagated up to the passage number 170. The entire HPV 33 genome of passages 1, 46 and 92 was sequenced from Ͼ20 overlapping PCR fragments ( Figure 2A ). HPV DNA from passage 1 showed single mutations in open reading frames (ORF) E6 (nt 81) and E4 (nt 3469), and two mutations in reading frames E2 (nt 3469 and 3759) and L2 (nt 4438 and 5220) compared with the prototype HPV 33 strain (29; GenBank accession no. M12732). The mutation in E6 was upstream of the coding region, the nt 3759 mutation in E2, as well as the nt 5220 mutation in L2, were silent. However, amino acid substitutions were introduced by the second mutation in E2 (T241→P; variable 'hinge' region in E2 protein), and the mutations in E4 (L48→F) and L2 (D77→N). The sequence variation pattern was the same for passages 46 and 92. However, when compared with passage 1, a large deletion in the HPV 33 DNA was found, encompassing more than half of the 3Ј part of E1 and major parts of the E2 and E4 genes ( Figure 2B ). In using the APOT assay (33), amplified products were obtained from passages 16 and 117 ( Figure 3 ) and subjected to DNA sequencing. The DNA sequence from passage 117 revealed a fusion transcript of viral and cellular DNA. The genomic breakpoint could be deduced from DNA sequences of PCR products of cellular DNA from passages 9 and 123, obtained by using specific HPV 33 forward primers and human cellular reverse primers ( Figure 2B and C) . A change from HPV33 to human sequence was found at position 1715 in the E1 ORF (3Ј side), and at position 3516 in the E2/E4 ORF (5Ј side) ( Figure 2C and D) . The cellular DNA sequence from the insertion points showed complete homology over at least 650 bp with the clone RP11-365F5 (accession no. AC032041) from chromosome 5, band 5p14.
However, there was a stretch of 16 nt immediately downstream of the HPV E1 sequence. This sequence showed 100% homology to the clone RP5-1128N12 (AL 109837) on chromosome 20 (nt 50166-50181). Only a single copy of HPV 33 was found, and there were no deletions or rearrangements in the chromosome region close to the site of integration. The other allele was HPV DNA unoccupied ( Figure 2E ). All the 22 subclones from passage number 92 were positive for both the 5Ј and 3Ј integration points by the presence of an amplicon of the correct size (229 and 166 bp, respectively) after agarose gel electrophoresis (not shown).
Dynamics of integration
The deduced DNA sequence of the integration point made possible the construction of a real-time PCR system for specific detection of integrated and episomal HPV 33. The primers and probe for this system are shown in Table 1 , and cover the 3Ј integration point. The physical state of HPV 33 in DNA from passages 9, 15-22, 29-31 (combined passage 29, 30 and 31), 38, 45, 50, 92, 108 and 123 were assayed by real-time PCR. There was a drastic change from episomal to integrated form between passages 21 and 22 ( Figure 4) . In passages following this, episomal form was below the detection limit (~5 copies/50 ng DNA). Low-level signals from integrated HPV 33 were, however, reproducibly found by real-time PCR already at passages 9, 16 and 18, but not at passages 15, 17, 19, 20 or 21 ( Figure 4) .
Selective growth advantage
Using the real-time PCR procedure for quantification of episomal and integrated HPV DNA described above, we show ( Figure 5A and B) that cells with integrated virus expanded and those with episomal virus were gradually depleted during passaging in all the different mixing ratios. The same changes were detectable also in the morphology and growth kinetics of the cells.
Karyotype and M-FISH analysis
Chromosome number of analyzed cells was mostly hypodiploid 41 but also some hypotetraploid cells were present. Chromosomes 1, 3, 4, 7, 8, 13, 14, 15, 18, 19, 21, 22 and X were either missing or took part in structural rearrangements as was shown in the earlier karyotype analysis on passages 28-30 (25) . Most of the structural rearrangements were unbalanced, leading to partial monosomy of chromosome regions 1q, 3p, 4q, 8p, 10p, 13q, 21q and partial trisomy of at least chromosome regions 8q, 12q 14q and 19. M-FISH analysis could confirm unbalanced translocations der(1)t(1;8) and der(3;19) also identified in the earlier study (25) and showed the origin of unknown additional material on derivate chromosomes der(4), der(7), add(14)(p),add(15)(p), add(18)(q23) and add(22)(p) seen but not characterized in the earlier study (25) (Figure 6B ). The M-FISH karyotype is presented in (Figure 6A ). The main line karyotypes of the cell line UT-DEC-1 on passage 150 according to conventional karyotype analysis and M-FISH analysis are 41,X,-X,der(1)t(1;8)(q?42;q12~13),der(3;19)(q10; q10),der(4)t(4;7;13)(4pter→4q13~21::7q?22→q?31::13q?→ 13q?),der(7)t(4;7)(?;p22)t(7;21)(q3;q?),-8,del(10)(p?12),13, der(14;19)(q10;p10),der (14)?inv dup(14)(q32q31-24)t(7;14) (?;?q32),der (15)t(8;15)(q12~13;q10), der(18)t(18;12)(q23;q? 15),-21,der(22;19)(q10;?p10)/41,idem, -der(1)t(1;8)(q?42; q12~13),ϩi(1)(p10).
Discussion
Integration, resulting in the disruption of the E1 or E2 reading frames, is common for high-risk HPV types detected in carcinomas, and disruption of either of these regulatory genes increases viral immortalization capacity (36) by upregulation of the E6 and E7 genes (37, 38) . However, it has been reported that the integration of foreign DNA into the host genome may be another consequence of genetic instability induced by highrisk HPV E6 or E7 expression (17, 39) . Multiple chromosomal integration sites have been detected for HPV 16 and 18 (11) (12) (13) 15, (40) (41) (42) (43) (44) , and chromosomal fragile sites have been suggested to be the preferential targets for viral integration (45, 46) . Several cytogenetic studies have demonstrated an association between common chromosomal fragile sites and the site of HPV integration (11, 12, 15, 43) . Interestingly, in the 5p14 site there is a common fragile site FRAE5 (47) (48) (49) , but at present, the significance of this finding for the integration of HPV 33 is unclear. This band also contains the integration site homology of Moloney murine retrovirus, Mlvi2 (50) .
The karyotype analysis on UT-DEC-1 on passage 150 showed that karyotypically the cell line had remained relatively stable when compared with the analysis carried out on passages 28-30 (25) . Recurrent integration at specific chromosomal locations, such as 8q21-q24 and 12q13-q15, has been detected for HPV 18 and 16 (8, (51) (52) (53) . Chromosome region 12q15 was seen to take part in a rearrangment in UT-DEC-1 in derivate chromosome der(18)t (18;12) . In addition to this, losses of heterozygosity have been described in chromosome regions 3p14-22, 4p16, 5p15, 6p21-22, 11q23 and 17p13.3 (54) . However, no rearrangements of these chromosomal regions were seen in UT-DEC-1. Amplification has been frequently mapped to the chromosome 3qϩ arm (3q24-28) in invasive carcinomas (55) .
In the present study, we have identified the precise integration site of HPV 33 in chromosome 5p14. The chromosome and M-FISH analysis showed that chromosome 5 is intact in UT-DEC-1. Our results support the view that the short arm of chromosome 5 is likely to be implicated in the tumor phenotype. Furthermore, we have identified a new HPV-associated locus. Several studies have indicated that the short arm of chromosome 5 might be of importance in cervical cancer and there might be a dose effect of gene located in chromosome 5 (56) (57) (58) (59) .
The integration event usually involves deletions in the viral flanking sites, often several kilobases in length. Likewise, the unoccupied allele usually is completely lost or deletions occur in large areas (60) . Our data show that the HPV 33 integration (3; 19) ,der(4)t(4;7;13),der(7)t(4;7;21),-8,10p-,-13,14qϩ,der (14;19) ,der(15)t(8; 15),der(18)t(12;18),der (19;22) ,-21. The derivate chromosome der(1)t(1;8) seen in most of the cells and in earlier study (25) is not present in this cell. Instead there is an isochromosome of the short arm of chromosome 1 seen also in two other cells. (B) The structurally rearranged derivate chromosomes from cell line UT-DEC-1 on passage 150 are presented both by G-banding and M-FISH: der(1)t(1;8)(wcplϩ,wcp8ϩ),der(3;19)(wcp19ϩ, wcp3ϩ),der(4)t(4;7;13)(wcp4ϩ,wcp7ϩ,wcp13ϩ),der(7)t(4;7;21)(wcp4ϩ, wcp7ϩ,wcp21ϩ),der(14)(wcp14ϩ,wcp?7ϩ),der(14;19)(wcp19ϩ,wcp14ϩ), der(15)t(wcp8ϩ,wcp15ϩ),der(18)t(12;18)(wcp18ϩ,wcp12ϩ),der(19;22) (wcp19ϩ,wcp22ϩ). occurred without a single nucleotide deletion, but with a gain of an unknown 16 nt sequence at the 3Ј end. Moreover, the presence of an intact second allele seems to be uncommon in previous cases involving other oncogenic HPVs (61, 62) . The presence of heterozygosity suggests that the effects of the integration are not due to the inactivation of a tumor suppressor gene. One possible explanation for the apparent heterozygosity could be that even at late passages, the cells are multiclonal. However, the subcloning experiment showing that all 22 subclones at passage 92 shared the same 5Ј and 3Ј integration sites, strongly argues against this.
Gallego et al. (61) have identified the precise integration site of HPV 18 in cervical carcinoma cell line SW756 in chromosome region 12q15, in the papillomavirus-associated locus -2 (PAL2). At the 5Ј breakpoint they could also detect an insertion of 17 nt of unknown origin between the cellular and viral sequences. They suggested that these extra nucleotides were a molecular remnant of the cellular sequences originally involved in the rearrangement induced by viral DNA recombination and integration. The extra sequences (16 nt) found by us had a 100% homology to chromosome 20 (AL109837). This rearrangement might also be explained as a result of HPV 33 integration. The absence of homology between the chromosomal junction sequences and HPV 33, excludes the possibility of homologous recombination as a mechanism for integration. A possible mode of HPV DNA integration could be the same as recently known to occur during adeno-associated virus or adenovirus integration (63, 64) .
HPV 33 integration has been studied previously using the immortalized cervical keratinocyte cell lines CK1 to CK12 (65, 66) . It should be noted that HPV 33 integrated at a single and identical site in CK1 to CK10 (subclones of the transfected cells), which was also evident in the HPV 33-carrying UT-DEC-1 cell line. However, our cell line differs from the CK cell lines in several important respects. First, our cell line was established from a natural low-grade dysplasia, which acquires a transformed phenotype, and cells containing integrated virus are selected from a population carrying mainly the episomal form of the virus during passaging. Moreover, the present study is the first one assessing the genomic variation of the entire HPV 33 genome, whereas the L1 region has mostly been studied in searching for HPV 33 variants. Earlier studies have shown nucleotide substitutions at nt 3603, 6637, 6664, 6666, 6674, 6679 and 6938, of which only two resulted in amino acid change (http://hpv-web.lanl.gov).
The data showed that there was a drastic change in the cell population from cells containing episomal to those containing integrated forms, occurring over one to two passages after a lag period of 20 passages. The most probable scenario regarding the physical state of HPV 33 in the UT-DEC-1 cell line is an early integration, followed by a selective enrichment of the cells containing integrated form. A positive selection for the cells containing integrated HPV is supported by the observation that HPV 16 and HPV 18 integrated into the cellular genome provided a growth advantage to these cells (7, 37, 66, 67) . The results of the mixing experiment with 'episomal' and 'integrated' cells supported such selective growth advantage for the latter UT-DEC-1 cells. We could also demonstrate that although the HPV 33 strain in our cell line carries a number of mutations compared with the prototype isolate, there is no change in the mutation pattern during the passaging.
What remains to be established at this point, is what cellular and/or viral factors are responsible for the onset of this dynamic change in the physical status and consequent expression pattern of the HPV 33 genome. Also, the identified fusion transcript with viral and cellular sequences needs further studies to explore its impact on transformation.
